Javascript must be enabled to continue!
Anti-apoptotic function of T-KTS+, T-KTS-, WT1+/+ and WT1+/- isoforms in breast cancer
View through CrossRef
Abstract
Background: WT1 was originally identified in Wilms tumor, a childhood kidney cancer. This gene was expressed in wide variety of solid cancers. Alternative splicing of WT1 transcript generates four major protein isoforms and thirty-six minor protein isoforms, each having different functional properties. WT1 gene has been considered as a tumor suppressor gene and anti-apoptotic protein. However, the mechanism of WT1 in breast cancer remains unclear. Objective: Evaluate the role of truncated WT1 isoforms (T-KTS+ and T-KTS-) and two major WT1 isoforms (+/+ and +/-) in apoptosis in breast cancer cell line, MCF-7. Materials and methods: RNA interference (RNAi) was employed in an attempt to define the role of WT1 in a breast cancer cell line (MCF-7). Furthermore, MCF-7 overe-xpressing cells that stably expressed two truncated WT1 isoforms (T-KTS+ and T-KTS-) or two major WT1 isoforms (+/+ and +/-) were generated and exposed to Doxorubicin. The mortality of cells was determined as a percentage of trypan blue-stained cells in total cells. The apoptotic molecules in apoptosis pathway were detected using RT-PCR, caspase-7 activity assay and Western blot analysis techniques. Results: Transfection of siRNAWT1 into MCF-7 cells resulted in decreasing of WT1 protein and related to the increasing in number of cell death and caspase-7 activity. Over-expression of T-KTS+, T-KTS-, WT1+/+ and WT1+/- isoforms protected cells from cell death induced by apoptosis-inducing agent, doxorubicin. Moreover, the expression of apoptotic p53, Bak and caspase-7 were decreased by the expression of all four WT1 isoforms, especially T-KTS- and T-KTS+ isoforms. Conclusion: T-KTS+ and T-KTS- isoforms as well as WT1+/+ and WT1+/- isoforms could function as an antiapoptotic protein in breast cancer cell line, MCF-7.
Walter de Gruyter GmbH
Title: Anti-apoptotic function of T-KTS+, T-KTS-, WT1+/+ and WT1+/- isoforms in breast cancer
Description:
Abstract
Background: WT1 was originally identified in Wilms tumor, a childhood kidney cancer.
This gene was expressed in wide variety of solid cancers.
Alternative splicing of WT1 transcript generates four major protein isoforms and thirty-six minor protein isoforms, each having different functional properties.
WT1 gene has been considered as a tumor suppressor gene and anti-apoptotic protein.
However, the mechanism of WT1 in breast cancer remains unclear.
Objective: Evaluate the role of truncated WT1 isoforms (T-KTS+ and T-KTS-) and two major WT1 isoforms (+/+ and +/-) in apoptosis in breast cancer cell line, MCF-7.
Materials and methods: RNA interference (RNAi) was employed in an attempt to define the role of WT1 in a breast cancer cell line (MCF-7).
Furthermore, MCF-7 overe-xpressing cells that stably expressed two truncated WT1 isoforms (T-KTS+ and T-KTS-) or two major WT1 isoforms (+/+ and +/-) were generated and exposed to Doxorubicin.
The mortality of cells was determined as a percentage of trypan blue-stained cells in total cells.
The apoptotic molecules in apoptosis pathway were detected using RT-PCR, caspase-7 activity assay and Western blot analysis techniques.
Results: Transfection of siRNAWT1 into MCF-7 cells resulted in decreasing of WT1 protein and related to the increasing in number of cell death and caspase-7 activity.
Over-expression of T-KTS+, T-KTS-, WT1+/+ and WT1+/- isoforms protected cells from cell death induced by apoptosis-inducing agent, doxorubicin.
Moreover, the expression of apoptotic p53, Bak and caspase-7 were decreased by the expression of all four WT1 isoforms, especially T-KTS- and T-KTS+ isoforms.
Conclusion: T-KTS+ and T-KTS- isoforms as well as WT1+/+ and WT1+/- isoforms could function as an antiapoptotic protein in breast cancer cell line, MCF-7.
Related Results
Structure of WT1 zinc fingers bound to its cognate DNA: Implications of the KTS insert
Structure of WT1 zinc fingers bound to its cognate DNA: Implications of the KTS insert
ABSTRACT
WT1 is a transcription factor with a DNA binding N-terminal domain containing four C2H2-type zinc fingers. In order to perform its role as a transcription ...
Breast Carcinoma within Fibroadenoma: A Systematic Review
Breast Carcinoma within Fibroadenoma: A Systematic Review
Abstract
Introduction
Fibroadenoma is the most common benign breast lesion; however, it carries a potential risk of malignant transformation. This systematic review provides an ove...
Desmoid-Type Fibromatosis of The Breast: A Case Series
Desmoid-Type Fibromatosis of The Breast: A Case Series
Abstract
IntroductionDesmoid-type fibromatosis (DTF), also called aggressive fibromatosis, is a rare, benign, locally aggressive condition. Mammary DTF originates from fibroblasts ...
The Role of Wilms’ Tumor Gene (WT1) Peptide-Specific Cytotoxic-T Lymphocytes in Selection of a Paroxysmal Nocturnal Hemoglobinuria (PNH) Clone.
The Role of Wilms’ Tumor Gene (WT1) Peptide-Specific Cytotoxic-T Lymphocytes in Selection of a Paroxysmal Nocturnal Hemoglobinuria (PNH) Clone.
Abstract
It is known that the expression of WT1 increases in leukemic cells from patients with acute and chronic leukemia, and that in leukemic patients, the WT1 eli...
Truncated WT1 protein isoform expression is increased in MCF-7 cells in a long-term estrogen depletion
Truncated WT1 protein isoform expression is increased in MCF-7 cells in a long-term estrogen depletion
Abstract
Background
The WT1 gene codes for a transcription factor that presents several protein isoforms with diverse biologica...
Abstract 1237: WT1, Wnt signaling and E-cadherin in prostate cancer
Abstract 1237: WT1, Wnt signaling and E-cadherin in prostate cancer
Abstract
Prostate carcinoma is the most common malignancy and second leading cause of death among American men. The molecular mechanisms that control the progression...
Abstract OI-1: OI-1 Decoding breast cancer predisposition genes
Abstract OI-1: OI-1 Decoding breast cancer predisposition genes
Abstract
Women with one or more first-degree female relatives with a history of breast cancer have a two-fold increased risk of developing breast cancer. This risk i...
Spanish Breast Cancer Research Group (GEICAM)
Spanish Breast Cancer Research Group (GEICAM)
This section provides current contact details and a summary of recent or ongoing clinical trials being coordinated by Spanish Breast Cancer Research Group (GEICAM). Clinical trials...

